Navigation Links
Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
Date:11/20/2013

-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, including risks related to the Company's ability to comply with the closing conditions or other conditions that might prevent the closing of the offering, the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioSpace Spotlights Northwests Life Science Community
2. Northwest Bio Implements Major Balance Sheet Clean-Up
3. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
4. Northwest Bio and Fraunhofer IZI Announce Milestones Reached
5. Chicago Celebrates First Informatics Week, Co-Chaired by Intelligent Medical Objects and Northwestern University
6. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
7. Northwest Bio Receives Regulatory Approval To Proceed With Its Phase III Trial In The UK
8. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
9. BioSpace Spotlights Northwests Life Science Community
10. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
11. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... USA, and Cardiff, UK (PRWEB) January 13, 2014 ... technology development leader with more than 20 years in ... for optics and photonics . Hainsey will serve as ... delighted to have Dr. Hainsey join SPIE as our ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... MAISONS-ALFORT, France, April 14 /PRNewswire-FirstCall/,-- Cephalon, Inc. (Nasdaq: ... has granted marketing authorization for EFFENTORA(TM), a buccal,tablet ... treatment of,breakthrough cancer pain (BTCP) in adult patients ... pain. The approval allows Cephalon,to market EFFENTORA in ...
... blood-based ColonSentry(TM) test -, TORONTO, April 14 ... on developing blood-based biomarker tests for the early,detection ... performance results from a large validation study of ... patient,s current risk for,colorectal cancer. This panel forms ...
... ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced ... 11, 2008 indicating that for the last 30,consecutive business ... closed,below $1.00 per share. As a result, the company ... continued listing set forth in,Marketplace Rule 4310(c)(4)., In ...
Cached Biology Technology:Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQ's Minimum Bid Price Requirement 2
(Date:4/17/2014)... 2014The development of stem cell therapies to cure a ... stem cell populations based on cell surface markers. Researchers ... marker that is highly expressed in a type of ... they describe in an article in BioResearch Open ... Inc., publishers. The article is available free on the ...
(Date:4/17/2014)... cartridge developed at Sandia National Laboratories and recently licensed ... and cheaper. , Bacillus anthracis , the ... all over the world and can cause serious, and ... bacteria can survive in harsh conditions for decades. In ... through skin contact, inhalation of spores or eating contaminated ...
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... 9, 2009 A nutritionist whose research was instrumental in ... Children (WIC) food subsidy will receive the March of Dimes ... maternal-fetal nutrition. Gail Harrison, Ph.D., MNS, , ... the University of California, Los Angeles School of Public Health, ...
... 150th anniversary this month of the publication of On ... Sciences (AIBS) is publishing open access two peer-reviewed articles ... , The two articles are by Kevin Padian of ... of Western Carolina University. Padian,s article, "Ten Myths About ...
... Conn.Researchers at Yale University have developed synthetic molecules capable ... HIV-infected cells, as well as to prostate cancer cells. ... the American Chemical Society , could lead to novel ... called "antibody-recruiting molecule targeting HIV" (ARM-H) and "antibody-recruiting ...
Cached Biology News:March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2New synthetic molecules trigger immune response to HIV and prostate cancer 2
... Science, which pioneered the blending of thermostable ... and Expand Long Template PCR Systems, now ... the first product of a family ... blend combines Taq DNA Polymerase with a ...
The HEPTEST assays provide a sensitive, simple, rapid, and convenient in vitro quantitation of heparin, low molecular weight heparins, and heparinoids in plasma and whole blood. Sample Type: wh...
...
... enzyme mix (Thermoprime Plus DNA Polymerase with ... four times higher fidelity than standard Taq ... Taq DNA polymerase, Amplifies DNA templates >20kb, ... PCR, PCR for cloning and mutagenesis We ...
Biology Products: